Plain-English translation of NCT04222062 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial compares two ways to treat brain tumors that have spread from cancer elsewhere in your body. Half of the patients will receive GLIADEL, a wafer containing chemotherapy that is placed directly into the surgical cavity after the tumor is removed. The other half will receive stereotactic radiosurgery (a focused radiation treatment) to the same area after surgery. The study is trying to figure out which approach better prevents the tumor from coming back.
When cancer spreads to the brain, surgeons remove the tumor, but it sometimes comes back in the same spot. Doctors want to know whether placing a chemotherapy wafer directly in that spot works better than using focused radiation to prevent this recurrence.
You likely qualify if…
You likely don't qualify if…
You will have brain imaging and thinking/memory tests before surgery. During your surgery to remove the tumor, you will be randomly assigned to receive either the chemotherapy wafer or to have radiation therapy planned for afterward. You'll have an MRI right after surgery to check how much tumor was removed. If you're in the radiation group, you'll receive that focused radiation treatment within 6 weeks of surgery. Over the following months, you'll have regular follow-up visits with MRI scans and cognitive testing to check for tumor recurrence and any changes in your thinking or memory.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States